Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma
- PMID: 24272080
- DOI: 10.1007/s13277-013-1360-4
Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma
Abstract
The principal aim of our study was to investigate the usefulness of serum protein and circulating mRNA of insulin-like growth factor-1 (IGF-1) as a diagnostic and prognostic tool in hepatocellular carcinoma (HCC). Fifty-four HCC patients and age- and sex-matched 20 healthy controls were enrolled into this study. Pretreatment serum IGF-1 and IGF-1 mRNA were determined by the solid-phase sandwich ELISA and quantitative RT-PCR method, respectively. The median age at diagnosis was 60 years, range 36-77 years; where majority of group were male (n = 48, 88.8%). All patients had cirrhotic history. Forty-six percent (n = 25) of patients had Child-Pugh score A, 30% (n = 16) had score B or C. All of the patients were treated with local therapies and none of them received sorafenib. The baseline serum IGF-1 mRNA levels were significantly higher in HCC patients than in the control group (p = 0.04), whereas no significant difference was observed for IGF-1 protein levels between the two group (p = 0.18). Patients with history of HBV infection, who were not treated, and who received multiple palliative treatment for HCC had higher serum IGF-1 mRNA levels (p = 0.03, 0.03, and 0.05, respectively). Poor performance status (p < 0.001), viral etiology of cirrhosis (p = 0.03), larger tumor size (p = 0.01), lower serum hemoglobin levels (p = 0.03), and not be treated for HCC (p = 0.001) related to worse survival. However, neither serum IGF-1 nor serum IGF-1 mRNA had significantly adverse effect on survival (p = 0.53 and 0.42, respectively).
Similar articles
-
Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma.Tumour Biol. 2014 Mar;35(3):2327-33. doi: 10.1007/s13277-013-1308-8. Epub 2013 Oct 20. Tumour Biol. 2014. PMID: 24142532
-
Preoperative Serum Insulin-Like Growth Factor 1 Level as a Prognostic Factor in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma.J Interferon Cytokine Res. 2018 Apr;38(4):153-160. doi: 10.1089/jir.2017.0107. J Interferon Cytokine Res. 2018. PMID: 29638204
-
Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort.BMC Cancer. 2018 Jul 31;18(1):774. doi: 10.1186/s12885-018-4677-y. BMC Cancer. 2018. PMID: 30064393 Free PMC article.
-
A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14. J Hepatol. 2014. PMID: 24045151 Free PMC article. Clinical Trial.
-
Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.Asian Pac J Cancer Prev. 2015;16(2):613-9. doi: 10.7314/apjcp.2015.16.2.613. Asian Pac J Cancer Prev. 2015. PMID: 25684496
Cited by
-
Cooperative effects of hepatitis B virus and TNF may play important roles in the activation of metabolic pathways through the activation of NF-κB.Int J Mol Med. 2016 Aug;38(2):475-81. doi: 10.3892/ijmm.2016.2643. Epub 2016 Jun 16. Int J Mol Med. 2016. PMID: 27315566 Free PMC article.
-
Prognostic significance of serum insulin-like growth factor-1 in patients with hepatocellular carcinoma following transarterial chemoembolization.Exp Ther Med. 2016 Feb;11(2):607-612. doi: 10.3892/etm.2015.2949. Epub 2015 Dec 16. Exp Ther Med. 2016. PMID: 26893654 Free PMC article.
-
HBx/WDR5 enhances IGF-1 transcription in hepatocellular carcinoma cells and promotes recruitment, infiltration, and activity of Treg cells.Immunol Res. 2025 Apr 8;73(1):69. doi: 10.1007/s12026-025-09620-x. Immunol Res. 2025. PMID: 40199768 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous